Jeffrey M Jacobson
Affiliation: Beth Israel Medical Center
- Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson
Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
J Infect Dis 188:1804-14. 2003..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)...
- Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542Jeffrey M Jacobson
Mount Sinai Medical Center, New York, New York 10029 Progenics Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
Antimicrob Agents Chemother 48:423-9. 2004..The findings support continued development of PRO 542 for salvage therapy of advanced HIV-1 disease...
- Immune-based therapies: an adjunct to antiretroviral treatmentJeffrey M Jacobson
Beth Israel Medical Center, Albert Einstein College of Medicine, New York, New York 10003, USA
Curr HIV/AIDS Rep 2:90-7. 2005..Strategies to reduce the immunopathogenic consequences of HIV infection with immunomodulating therapies are conceivable. Ultimately, eradication of the infection will require methods to target the latent memory T-cell reservoir of virus...
- Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068Jeffrey M Jacobson
Beth Israel Medical Center and Albert Einstein College of Medicine, New York, NY 10003, USA
J Infect Dis 194:623-32. 2006....
- Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infectionChristopher J Bruno
Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
J Antimicrob Chemother 65:1839-41. 2010..Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1...
- CCR5 monoclonal antibodies for HIV-1 therapyWilliam C Olson
Progenics Pharmaceuticals Inc, Tarrytown, NY 10591, USA
Curr Opin HIV AIDS 4:104-11. 2009..Two CCR5 mAbs have entered clinical testing and have successfully completed proof-of-concept studies in HIV-infected individuals, providing initial information on the potential therapeutic utility of these agents...
- Effects of highly active antiretroviral therapy on HIV-1-associated oral complicationsZahida Parveen
Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Curr HIV Res 5:281-92. 2007..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented...
- Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIVRosalind G Hoffman
Mount Sinai Medical Center, New York, New York 10029, USA
Psychosomatics 44:417-20. 2003
- HIV- and AIDS-related knowledge, awareness, and practices in MadagascarNicole M Lanouette
Mount Sinai School of Medicine, New York, NY, USA
Am J Public Health 93:917-9. 2003
- The prevalence of distress in persons with human immunodeficiency virus infectionMaryAnn Cohen
AIDS Center, Box 1009, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
Psychosomatics 43:10-5. 2002..The HADS and the Distress Thermometer showed a good correlation with each other (P < 0.0005), and these questionnaires can provide a simple and efficient method for rapid screening in an HIV clinic setting...
- A reporting tool for real-time assessment of study data availabilityRonald J Bosch
Clin Trials 1:339-40. 2004..A simple framework for assessing and reporting data availability in an ongoing clinical trial is described. Protocol requirements, visit schedules and data availability are combined into a simple report to track the progress of a study...
- Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Marion G Peters
University of California, San Francisco, San Francisco, CA, USA
Hepatology 44:1110-6. 2006..In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV...
- Evaluation of cellular immune responses in subjects chronically infected with HIV type 1Tong Ming Fu
Merck Research Laboratories, West Point, PA 19486, USA
AIDS Res Hum Retroviruses 23:67-76. 2007..Our findings suggest that the high levels of ELISpot responses in chronically infected subjects were reflective of their persistent viral infection...
- Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patientsMelanie A Thompson
AIDS Research Consortium of Atlanta, Georgia, USA
AIDS 19:1607-15. 2005..To evaluate the pharmacodynamics and safety of escalating doses of amdoxovir (DAPD) monotherapy administered to treatment-naive and experienced HIV-1-infected patients over 15 days...
- A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)Robert S Wallis
The University Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
J Acquir Immune Defic Syndr 32:281-6. 2003..The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted...
- A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102Keith Henry
HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis, MN 55415, USA
J Acquir Immune Defic Syndr 42:140-8. 2006..By boosting CD4 T-cell counts, interleukin 2 (IL-2) could safely prolong the duration of treatment interruption (TI) in a CD4-driven strategy...
- Trials that matter: CD4+ T-lymphocyte count-guided interruption of antiretroviral therapy in HIV-infected patientsJeffrey M Jacobson
Ann Intern Med 146:682-3. 2007
- Actin integrity is indispensable for CD95/Fas-induced apoptosis of HIV-specific CD8+ T cellsConstantinos Petrovas
Department of Microbiology and Immunology, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Drexel University, 2900 Queen Lane, Philadelphia, PA 19129, USA
Apoptosis 12:2175-86. 2007....